VC-backed Bicycle Therapeutics goes public
UK-based Bicycle Therapeutics, a biopharmaceutical firm, has raised about $60.7 million for its IPO after pricing its over 4.3 million shares at $14 per share. The stock began trading May 23, 2019 on the NASDAQ under the ticker symbol "BCYC." Goldman Sachs, Jefferies LLC and Piper Jaffray & Co are the lead underwriters. Bicycle Therapeutics' pre-IPO backers included Vertex Ventures HC, Cambridge Innovation Capital, Longwood Fund, Novartis Venture Fund, SROne, SVLS and Atlas Venture.
23 May 2019•3 mins read
